Drug Trial Radar · NCT05565378
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
351
Actual
Start
Oct 14, 2022
Primary completion
Oct 26, 2026
Study completion Dec 6, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- iTeos Therapeutics
- First posted
- Oct 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Conditions
- Lung Cancer, Non-Small Cell
Interventions
PembrolizumabDrug
Pembrolizumab will be administered.
DostarlimabDrug
Dostarlimab will be administered
BelrestotugDrug
Belrestotug will be administered.
NelistotugDrug
Nelistotug will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 228 weeks
- Number of Participants with TEAEs or SAEs leading to dose modifications or treatment discontinuationTime frame: Up to 228 weeks
Locations
99 sites in 22 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
Chattanooga, Tennessee
GSK Investigational Site
Morgantown, West Virginia
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Cipoletti Rio Negro, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
GSK Investigational Site
Florida, Argentina
GSK Investigational Site
Mar del Plata, Argentina
GSK Investigational Site
San Juan, Argentina
GSK Investigational Site
Santa Fe, Argentina
GSK Investigational Site
Wilrijk, Belgium
GSK Investigational Site
Barretos, Brazil
GSK Investigational Site
Porto Alegre, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Vitória, Brazil
GSK Investigational Site
Oulu, Finland
GSK Investigational Site
Tampere, Finland
GSK Investigational Site
Turku, Finland
GSK Investigational Site
Vaasa, Finland
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Caen, France
GSK Investigational Site
Marseille, France
GSK Investigational Site
Quimper, France
GSK Investigational Site
Strasbourg, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Heidelberg, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Großhansdorf, Schleswig-Holstein, Germany
GSK Investigational Site
Jena, Thuringia, Germany
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Pylaia Thessaloniki, Greece
GSK Investigational Site
Thessaloniki, Greece
GSK Investigational Site
Athens, Attica, Greece
GSK Investigational Site
Chaïdári, Attica, Greece
GSK Investigational Site
Thessaloniki, Central Macedonia, Greece
GSK Investigational Site
Larissa, Thessaly, Greece
GSK Investigational Site
Budapest, Hungary
GSK Investigational Site
Gyöngyös, Hungary
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.